ACOR Acorda Therapeutics, Inc. featured news, full reports, and detailed charts
Acorda Therapeutics, Inc. (ACOR) Wrap Up:
We are a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, or MS, spinal cord injury, or SCI, and other disorders of the central nervous system, or CNS. Our marketed product, Zanaflex Capsules, is approved by the U.S. Food and Drug Administration (FDA) for the management of spasticity. Our lead product candidate, Fampridine-SR, is in Phase 3 development for the improvement of walking ability in patients with MS. In September 2006, we reported positive Phase 3 clinical trial results from our first Phase 3 trial and we expect to have results from our second Phase 3 trial of Fampridine-SR in the latter part of the second quarter of 2008. If the results of this trial are favorable, we intend to submit a New Drug Application (NDA) to the FDA in the first quarter of 2009. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0001047469-08-002781.html#FIS_BUSINESS"www.acorda.com
174 Employees
Founded in 1995
Acorda Therapeutics, Inc. (ACOR:NASDAQ)
LAST $23.90 USD
CHANGE TODAY +0.25 1.06%
VOLUME 619.6K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Acorda Therapeutics, Inc. (ACOR)
|
OPEN
$23.48
|
PREVIOUS CLOSE
$23.65
|
|
|
DAY HIGH
$24.09
|
DAY LOW
$23.13
|
|
|
52 WEEK HIGH
02/24/09 - $29.27
|
52 WEEK LOW
11/20/08 - $14.42
|
|
|
MARKET CAP
911.1M
|
AVERAGE VOLUME 3 mo
394.9K
|
|
|
DILUTED EPS TTM
$-2.16
|
SHARES OUTSTANDING
38.1M
|
|
|
ACOR Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
The Fight Over Drug Data Mining
06/10/2009 4:56 PM ET
Suite Scams
03/27/2008 5:00 PM ET
ACOR Top Compensated Officers
Dr. Ron Cohen M.D.
Founder, Chairman, Chief Executive Officer an...
Age: 53
Total Annual Compensation: $668.2K
Mr. David Lawrence M.B.A.
Chief Financial Officer and Principal Account...
Age: 53
Total Annual Compensation: $334.5K
Ms. Jane Wasman J.D.
Executive Vice President, General Counsel and...
Age: 53
Total Annual Compensation: $434.7K
Dr. Andrew R. Blight Ph.D.
Chief Scientific Officer
Age: 58
Total Annual Compensation: $407.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Acorda Therapeutics, Inc. (ACOR)
Acorda Therapeutics, Inc. - Conference Presentation Call
11/16/2009
Acorda Therapeutics, Inc. - Conference Presentation Calls
Acorda Therapeutics Inc. Reports Un-Audited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/3/2009
Acorda Therapeutics Inc. reported un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2009. The company reported a net loss of $19.4 million for the quarter ended September 30, 2009, or $0.51 per diluted common share, compared to a net loss of $18.9 million, or $0.53 per diluted common share, for the same quarter in 2008. Total net revenue was $15.214 million, against $12.466 million of previous year period. Operating loss was $19.001 million, compared to $19.254 million for the same period last year. For the nine months ended September 30, 2009, net loss was $61.467 million or $1.63 basic and diluted loss per share on revenue of $40.233 million compared to net loss of $54.109 million or $1.65 basic and diluted loss per share on revenue of $35.365 million for the same period last year. Operating loss was $59.224 million compared to $52.651 million for the same period last year.
Acorda Therapeutics, Inc., Q3 2009 Earnings Call, Nov--03-2009
10/27/2009
Acorda Therapeutics, Inc., Q3 2009 Earnings Call, Nov-03-2009
ACOR Competitors
| Company | Last | Change |
| Biogen Idec Inc | $46.38 USD | +0.53 |
| Elan Corporation | €4.36 EUR | +0.039 |
| Novadel Pharma Inc | $0.23 USD | -0.0199 |
| Teva Pharmaceutical Ind | $52.72 USD | -0.32 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ACOR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 17.1x |
|
| Price/Book | 5.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 11.6x |
|
|
ACOR |
||
|
ACOR transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Acorda Therapeutics, Inc.
More news for ACOR
Q3 2009 Acorda Therapeutics Earnings Release - Before Market Open
Earnings Announcements for Tuesday, November 3CompanySymbolTimeConferenceCall3D SystemsTDSCAfter Market CloseListenAbengoaABG.MC11:45 pm ETListenAcorda TherapeuticsACORBefore Market OpenListenAECON GROUP INCARE.TOAfter Market CloseAGA Medical Holdings, Inc.AGAMAfter Market CloseListenAllis-Chalmers Energy Inc.ALYBefore Market OpenAllos Therapeutics, Inc.ALTHAfter Market CloseListenAlpha Natural Resources, Inc.ANRBefore Market OpenAmerican Capital Ltd.ACASAfter Market CloseListenAmerican Tower Corp.AMT07:00 am ETListenAmeriSourceBergenABCBefore Market OpenListenAMICAS INCAMCSAfter Market CloseAMTRUST FINANCIAL SERVICES INCAFSIAfter Market CloseANIMAL HEALTH INTERNATIONAL INCAHIITime Not SuppliedAnoto Group ABAOTOF.PK02:30 am ETAnworth Mortgage Asset...Click here to read the whole Article (external link)
ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
Show all filings for ACORDA THERAPEUTICS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for ACORDA THERAPEUTICS INC 3-Nov-2009Results of Operations and Financial Condition, Financial Statements and E Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information p...Click here to read the whole Article (external link)
Acorda Therapeutics 3Q loss widens on costs
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Acorda Therapeutics Earnings Call scheduled for 8:30 am ET today
Call DetailsAcorda Therapeutics Earnings Conference Call (Q3 2009)Tue, Nov 3, 2009, 8:30 am EasternAbout Acorda Therapeutics (NasdaqGM:ACOR)Other Calls Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company’s lead product candidate is Fampridine-SR, which completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.More Info:Quote |Profile |Reports |Research |Msgs |Insider |Financials | ...Click here to read the whole Article (external link)
ACORDA THERAPEUTICS INC Financials
PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue15,214 12,549 12,469 12,462 Cost of Revenue2,767 2,951 2,559 2,838 Gross Profit12,447 9,598 9,910 9,624 Operating ExpensesResearch Development8,198 7,867 7,917 10,846 Selling General and Administrative23,250 23,926 20,022 19,566 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(19,001)(22,195)(18,028)(20,788)Income from Continuing OperationsTotal Other Income/Expenses Net275 373 813 1,146 Earnings Before Interest And Taxes(18,726)(21,822)(17,216)(19,642)Interest Expense704 1,507 1,492 589 Income Before Tax(19,430)(23,329)(18,708)(20,232)Income Tax Expense - - - - Minority Interest - - - - Net Income From Continuing Ops(19,430)(23,329)(18,708)(20,232)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - - ...Click here to read the whole Article (external link)
ACORDA THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our consolidated financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q. Background Since we commenced operations in 1995, we have devoted substantially all of our resources to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the central nervous system (CNS). Our marketed drug, Zanaflex Capsules, is U.S. Food and Drug Administration (FDA)-approved for the management of spasticity. We announced positive results from a Phase 3 clinical trial of our lead product candidate, Fampridine-SR, for the improvement of walking ability in people with MS in September 2006. A second Phase 3 trial of Fampridine-SR in MS, MS-F204, was initiated in June 2007 and favorable results from that study were released in June 2008. The objective of this study was to show that individuals treated with Fampridine-SR are significantly more likely to have consistent improvements in their walking than those treated with placebo. A Thorough QT cardiac study was initiated in September 2007 and favorable results from that study were released in January 2008. This study evaluated the potential of Fampridine-SR to cause an increase in the electrocardiographic QT interval. Fampridine-SR, at both therapeutic and supratherapeutic doses, was found to be no different than placebo. On January 30, 2009, we announced the submission of a New Drug Application (NDA) to the FDA for Fampridine-SR. The Fampridine-SR NDA submission is based on data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two Phase 3 trials that involved 540 people ...Click here to read the whole Article (external link)
New Star Analyst Rankings for Acorda Therapeutics, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
(Nasdaq: ACOR - Newsth Annual Healthcare Conference on Tuesday, November 17, 2009 at 3:10 p.m. ET at the St. Regis Hotel in New York, NY. A live webcast of the presentation can be accessed under “Calendar of Events†in the Acorda Investor Relations section of the website at www.acorda.com, or you may use the link: http://www.wsw.com/webcast/lz6/acor/.Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection. An archived version of the webcast will be available until February 17, 2010 on the Acorda website in the Investor Relations section; to access please use the link ...Click here to read the whole Article (external link)
Would you like to leave a comment about Acorda Therapeutics, Inc. ACOR
Find out what social network information about Acorda Therapeutics, Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Acorda Therapeutics, Inc. there is more great information available at Realpennies.com